Nuvance Health, formerly the Western Connecticut Health network, a regional network of hospitals, includes Danbury and Norwalk Hospital. A clinical trial is now available at these facilities for patients battling advanced-stage cancer who happen to also have a KRAS...
KRAS
Category
CodeBreak 100 Study: Sotorasib Zaps Lung & Colon Cancer Tumors in Majority of Participants
KRAS is a cancer gene has been studied for about 40 years, reports Memorial Sloan Kettering Cancer Center (MSKCC). It is known to be associated with a number of cancers such as about 25% of lung cancers and between 33% and 50% of colon and rectal cancers. Until...
DOE-Funded UC Berkeley’s Advanced Light Source Contributes to a Pathbreaking Experimental Cancer Drug
Amgen’s AMG 510, the first therapy to reach clinical trials that inhibits a mutant KRAS protein, has demonstrated promising safety and efficacy results based on preliminary animal studies and clinical trials ongoing. It is now entering Phase II clinical trials. It got...
Leading KRAS Inhibitor Candidate for Patients with Lung & Colon Cancer, MRTX849 Producing Positive Data in Phase I Trial
In a Phase 1/2 trial MRTX849, an investigational KRAS G12C inhibitor has demonstrated clinical activity, including objective responses in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). Although a maximum targeted dose has not yet been...
Beth Israel Deaconess Medical Center Finding: Precision Medicine isn’t Precise Enough Yet for Cancer
The KRAS gene is one of the commonly mutated genes in cancer. More than 40% of colorectal cancers have a mutated KRAS gene, or oncogene, that is at least partially responsible for cancer development. Mutated KRAS genes are commonly found in other cancers as well....